The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone
| العنوان: | The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone |
|---|---|
| المؤلفون: | Tien-Hsing Chen, Wei-Chiao Sun, Feng-Hsuan Liu, Victor Chien-Chia Wu, Yan-Rong Li, Chihung Lin, Chi-Hung Liu, Pei-Yi Fan, Ching-Chung Hsiao |
| المصدر: | Journal of Personalized Medicine Volume 11 Issue 9 Journal of Personalized Medicine, Vol 11, Iss 828, p 828 (2021) |
| بيانات النشر: | MDPI, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, Bladder cancer, Combination therapy, business.industry, type 2 diabetes mellitus, Hazard ratio, Medicine (miscellaneous), Type 2 Diabetes Mellitus, medicine.disease, mortality, Confidence interval, Article, Internal medicine, medicine, Medicine, bladder cancer, pioglitazone, business, Database research, Pioglitazone, Reference group, sodium glucose cotransporter-2 (SGLT-2) inhibitors, medicine.drug |
| الوصف: | Background: Either sodium-glucose cotransporter-2 (SGLT-2) inhibitors or pioglitazone (Pio) has doubtful issues of bladder cancer, especially for the combination therapy with these two drugs. Our study aimed to investigate the risk of bladder cancer under combination therapy of SGLT-2 inhibitors and Pio. Materials and Methods: We included 97,024 patients with type 2 diabetes mellitus (T2DM) in the Chang Gung Research Database in Taiwan from 1 January 2016 to 31 December 2019. The primary outcome was newly diagnosed bladder cancer after combination therapy with SGLT-2 inhibitors and Pio. Group 1 received both study drugs, group 2 received SGLT-2 inhibitors, group 3 received Pio, and group 4 received non-study drugs (the reference group). The secondary outcome in each group was all-cause mortality. Results: In group 1, no newly diagnosed bladder cancer was detected after a mean 2.8-year follow-up and all-cause mortality decreased significantly (adjusted hazard ratio (AHR), 0.70 95% confidence interval (CI), 0.54–0.92) in comparison to the reference group (group 4). In group 2 and group 3, no trend of increased bladder cancer was observed (group 2: AHR 0.49, 95% CI 0.05–4.94 group 3: AHR 0.48, 95% CI 0.15–1.58) and it still reduced all-cause mortality (group 2: AHR 0.83, 95% CI 0.70–0.99 group 3: AHR 0.90, 95% CI 0.83–0.99). Conclusions: In T2DM patients without previous or active bladder cancer, the combination therapy of SGLT-2 inhibitors and Pio was not associated with newly diagnosed bladder cancer and had lower all-cause mortality. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2075-4426 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba8882c102f2f4b1e4b4dd3506ecdf98 http://europepmc.org/articles/PMC8472235 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....ba8882c102f2f4b1e4b4dd3506ecdf98 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20754426 |
|---|